IRB23-1681: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (clinicaltrials.gov) - Sep 2, 2026 - P1 | N=18 | Recruiting | Sponsor: University of Chicago | Trial completion date: May 2026 ➔ May 2029 | Trial primary completion date: May 2026 ➔ May 2029
Trial completion date • Trial primary completion date • Myeloproliferative Neoplasm • Oncology • IDH1
|